Ampion™ reduces all-cause mortality in covid-19 respiratory distress by nearly 80%

Englewood, colo., april 27, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today revealed positive results in its ap-014 phase i clinical trial utilizing inhaled ampion in treating respiratory distress in patients as a result of covid-19.
AMPE Ratings Summary
AMPE Quant Ranking